title: ETO sequence may be dispensable in some AML1-ETO leukemias.
authors.forename: Adriana
authors.initials: A
authors.lastname: Lasa
authors.forename: Josep F
authors.initials: JF
authors.lastname: Nomdedeu
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Carnicer
authors.forename: Andreu
authors.initials: A
authors.lastname: Llorente
authors.forename: Jorge
authors.initials: J
authors.lastname: Sierra
mesh_terms: D000208:Acute Disease; D000328:Adult; D001483:Base Sequence; D050676:Core Binding Factor Alpha 2 Subunit; D004252:DNA Mutational Analysis; D004268:DNA-Binding Proteins / Q000235:genetics*; D006801:Humans; D007951:Leukemia, Myeloid / Q000209:etiology / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011518:Proto-Oncogene Proteins; D000075142:RUNX1 Translocation Partner 1 Protein; D014157:Transcription Factors / Q000235:genetics*; D014178:Translocation, Genetic
chemical_list: C107844:AML1-ETO fusion protein, human; D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins; D015514:Oncogene Proteins, Fusion; D011518:Proto-Oncogene Proteins; D000075142:RUNX1 Translocation Partner 1 Protein; C082222:RUNX1T1 protein, human; D014157:Transcription Factors